A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy (CT-RT) for Unresectable Stage IIIA/IIIB NSCLC: A Report of Toxicities and Clinical Response

BACKGROUND: The objective of this Phase I trial was to determine dose-limiting toxicities (DLT) and the maximally tolerated dose of the radiosensitizer Nelfinavir in combination with concurrent chemoradiotherapy (CT-RT) in locally advanced non-small cell lung cancer (NSCLC). METHODS: Nelfinavir (Dos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rengan, R., Mick, R., Pryma, D., Rosen, M.A., Lin, L., Maity, A., Evans, T. L., Stevenson, J. P., Langer, C.J., Kucharczuk, J., Friedberg, J., Prendergast, S., Sharkoski, T., Hahn, S.M.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3310889/
https://ncbi.nlm.nih.gov/pubmed/22425919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3182435aa6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars